中国实用外科杂志

• 院士论坛 • 上一篇    下一篇

我国肝癌诊疗和临床研究进展

樊    嘉   

  1. 复旦大学附属中山医院 复旦大学肝癌研究所,上海 200032
  • 出版日期:2019-10-01 发布日期:2019-10-10

  • Online:2019-10-01 Published:2019-10-10

摘要:

肝癌作为我国最常见的恶性肿瘤之一,其疾病背景和临床诊治与国外有所不同,具有中国特色。近年来,我国在肝癌诊疗和研究方面取得了长足的进步。在肝癌的早期诊断方面,以循环微小核糖核酸(miRNA)、循环肿瘤细胞(CTC)、循环肿瘤DNA(ctDNA)为代表的液体活检技术取得一系列进展和成果,极大推动了肝癌的早诊早治。在手术治疗方面,通过不断探索新的手术方式、手术适应证以及术后转移复发干预策略,使更多病人得到手术切除机会,同时降低了术后肝癌转移复发的风险,显著延长病人总生存时间。此外,肝癌临床研究日益受到重视,部分临床试验的结论作为重要的循证医学证据,指导肝癌诊疗规范推陈出新,为我国肝癌病人“量体裁衣”,更加符合中国肝癌的疾病特点。

关键词: 肝癌, 液体活检, 外科治疗, 临床试验, 诊疗规范

Abstract:

The advances in diagnosis,treatment and clinical research of hepatocellular carcinoma in China        FAN Jia. Liver Cancer Institute and Zhongshan Hospital,Fudan University,Shanghai 200032,China
Abstract    As one of the high frequent malignancies in China,liver cancer has different disease background and clinical management modalities compared with that in foreign countries. In recent years,China has made great progress in the diagnosis and treatment of liver cancer. In the early diagnosis,a series of accomplishments have been achieved in liquid biopsy techniques represented by circulating microRNA (miRNA), circulating tumor cell (CTC),and circulating tumor DNA (ctDNA),which remarkably promoted the early diagnosis of liver cancer. In the surgical treatment,through continuous exploration of novel surgical methods,surgical indications and anti-recurrence and -metastasis strategies,patients get more surgical opportunities,lower risks of metastasis and relapse and significantly prolonged overall survival. In addition,clinical research of liver cancer has received unprecedented attention. The conclusions of some clinical trials have served as important evidence to direct the development of guidelines,and to choose appropriate treatment strategies for patients in China,which is more in line with the characteristics of liver cancer in China.

Key words: hepatocellular carcinoma, liquid biopsy, surgical treatment, clinical trials, guidelines for diagnosis and treatment